We are delighted to announce that Chris Kirton joins us as our Chief Operating Officer; a senior operations leader with over 15 years of drug development, commercial and operational management experience in both industry and academia. Chris joins us from a leading supplier in the biotech industry and takes up his leadership role at Axol, bringing with him his extensive operational experience at the highest levels, focusing Axol's position and supporting growth within the Human iPSC-Derived Stem Cell market.

    Welcome, Chris!

    Share this post:

    Axol Bioscience appoints Liam Taylor as Chief Executive Officer

    Major success for MESO-BRAIN partners will lead to breakthrough technology for developing new brain models